Timothy Y Y Lai1, Chui Ming Gemmy Cheung. 1. *Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong; †2010 Retina & Macula Centre, Tsim Sha Tsui, Kowloon, Hong Kong; ‡Singapore National Eye Centre, Singapore; §Eye Academic Clinical Program, Duke-NUS Graduate Medical School, Singapore; ¶Singapore Eye Research Institute, Singapore; and ‖Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Abstract
PURPOSE: To review and summarize the latest developments in the diagnosis and management of myopic choroidal neovascularization (mCNV). METHODS: A review of the literature was performed, focusing on tests and investigations for diagnosing mCNV, as well as the key treatment options available for mCNV. RESULTS: Standard essential tests and investigations for diagnosing mCNV include spectral-domain optical coherence tomography for screening, fluorescein angiography for confirmation, and indocyanine green angiography and fundus autofluorescence for providing supplementary information. The current first line treatment of mCNV is the use of anti-vascular endothelial growth factor therapy. CONCLUSION: Various investigations can assist the differentiation of mCNV from other coexisting retinal pathologies associated with myopia or choroidal neovascularization resulting from other causes. Prompt use of anti-vascular endothelial growth factor therapy has good efficacy and safety in the treatment of mCNV.
PURPOSE: To review and summarize the latest developments in the diagnosis and management of myopic choroidal neovascularization (mCNV). METHODS: A review of the literature was performed, focusing on tests and investigations for diagnosing mCNV, as well as the key treatment options available for mCNV. RESULTS: Standard essential tests and investigations for diagnosing mCNV include spectral-domain optical coherence tomography for screening, fluorescein angiography for confirmation, and indocyanine green angiography and fundus autofluorescence for providing supplementary information. The current first line treatment of mCNV is the use of anti-vascular endothelial growth factor therapy. CONCLUSION: Various investigations can assist the differentiation of mCNV from other coexisting retinal pathologies associated with myopia or choroidal neovascularization resulting from other causes. Prompt use of anti-vascular endothelial growth factor therapy has good efficacy and safety in the treatment of mCNV.
Authors: Timothy Y Y Lai; Giovanni Staurenghi; Paolo Lanzetta; Frank G Holz; Shiao Hui Melissa Liew; Sabine Desset-Brethes; Harry Staines; Philip G Hykin Journal: Retina Date: 2018-08 Impact factor: 4.256
Authors: Robin D Hamilton; Andreas Clemens; Angelo Maria Minnella; Timothy Y Y Lai; Hong Dai; Taiji Sakamoto; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Cornelia Dunger-Baldauf; Frank G Holz Journal: PLoS One Date: 2020-01-21 Impact factor: 3.240